Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2022 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (174)	9/1/2022 6:23:14 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 267

Tech, Here is one for your contest--actually I think I have in my SI portfolio---it, along with most of the biotech market has been on a downer this year. In my personal portfolio I own the stock and have been adding over recent weeks---take a look at the action today---up 25% on massive trading volume: Here is a biotech that IMO has the potential for making a return to the level seen in the last 52 weeks—that being near the $7.00 a share. 2022 has been a horrendous year to own shares in the company—but the underlying fundamentals have remained in place. My initial entry level is around the $5.00 level, but over recent weeks I’ve added to my position---the lowest level for buying was $1.65. But I’m still underwater on my position. Eyenovia (EYEN): I Can See You Better - Now \| Seeking Alpha This SA article gives the background for the company and the unexpected decision of the FDA switching criteria for the trial design for their unique delivery device and potential eye products. However, long term, the ensuing delay has been advantageous for the company because with their current ongoing Phase III product clinical trial they will have data for the device that can be applied now for the NDA submission, instead of later. This Phase III trial, assuming it is approved, will compete in a multi-billion-dollar market and their delivery method will be unique to the market. Over the last few weeks, I’ve watched the daily trading in the stock to see if any trend is developing in the trading pattern and interest level from institutional buyers. Today—on no news—the stock opened a few pennies up and then climbed the stairs in constant upward movement---normal trading is around 180,000 shares. Today it traded 1.6 million shares –up 25%. The buyers were there! The Phase III data should happen in the immediate future—if it indicates the efficacy and safety profile seen in the Phase II data---we could see the $6.00 level very quickly. The resubmission of their earlier NDA for the dilatation process has been promised by the end of the year. The FDA requesting the new data for the device, there was no questions about the products efficacy or safety. Plus, upon resubmitting the FDA review should happen within six months---since they have already declared the initial NDA had no issues other than more data on the delivery device. Keep in mind—only weeks ago this stock was trading around sub-$1.50. The largest insider investor has been buying since the FDA delayed their initial NDA application. The next few days could be interesting –one can hope it will be interesting on the positive side.

To: technetium who wrote (174)

9/4/2022 7:42:57 PM

From: technetium

2 Recommendations

Recommended By
BulbaMan
Lance Bredvold

Read Replies (2) | Respond to of 267

Another week of sad trombones, though once again the biotech indices were less bad (off -1.1% or -1.6%) than the NASDAQ composite (down -4.2%).

In the list of “winner” stocks for last week, there are no big standouts. Indeed the top stock is the Candian firm BTI.V, up 26% for the week to a weekly “close” at 19 cents (Canadian). But this result is pretty tenuous in that the stock is extremely thinly traded, with only four (!) trades during the week, the last being 300 shares late Thursday for 19 cents, with a fairly large spread (the “bid” value was 15.5 cents and the “Ask” was 19 cents) (The Toronto exchange was closed Friday). The previous sale was 10,500 shares at the market open Wednesday for 15.5 cents, the same price given for the weekly open, and only a 3% improvement on last weeks close.

Then there is the second place finisher, AYLA, whose +18.7% gain built on the previous week’s +26.7%. But, both week’s action was restricted to trades on Friday, with no apparent news either week to justify the change, On the losing side, CABA crashed on Monday (off f-47% for the week), almost certainly based on disappoint with an update on a drug trial presented at the EADV Congress that day. The second worst loser, TOMDF, -33%, more than erased it’s previous week's second place gain of +35%.

As previously mentioned, ATHX had a 25 to 1 reverse split, reflecting a poor performance.

In contrast to other recent weeks, the contest portfolios generally were bigger losers than the bio-tech indices, dropping -2.2% in the median for the week. As a result now all of the portfolios have slipped into the red, YTD, and only six of the portfolios managed a net positive for the week, though the top five of the list are members of the the top ten YTD list, which might say something. They obviously tended to improve their position in the list, which mixed up the order of the 3rd to 10th place YTD portfolios. Bulbaman took his 3rd place finish in the week’s performance to return to the top ten YTD list after only a single week’s absence.

		Report Time Ranges
			From	To
		Recent	8/26/22	9/2/22
		YTD	12/31/21	9/2/22
Index Performance
			Symbol	Recent	YTD
			^IXIC	-4.21%	-25.66%
			^NBI	-1.14%	-18.13%
			^SPSIBI	-1.57%	-25.21%
Share Performance
Recent				YTD
Top 5		Bottom 5		Top 5		Bottom 5
BTI.V	26.667%	CABA	-47.374%	OPTN	122.84%	GNCA	-99.13%
AYLA	18.675%	TOMDF	-32.840%	CBIO	113.35%	VLON	-93.48%
OMER	18.063%	ATHX	-22.154%	ALDX	73.50%	PTE	-93.12%
FULC	12.917%	RNLX	-22.134%	FENC	67.95%	PLXP	-90.51%
APLS	12.287%	LQDA	-21.971%	ESPR	57.20%	PRQR	-90.39%
			Top 10 Portfolio YTD		YTD(Portfolio - SPSIBI)	Rec	Rec(Port. - SPSIBI)
			DIEGOSAN	-0.85%	24.37%	-1.470%	0.096%
			BRENDAN_49	-10.80%	14.41%	-2.298%	-0.732%
			DEW DILIGENCE	-11.07%	14.15%	2.715%	4.281%
			TECHNETIUM	-15.98%	9.24%	2.223%	3.789%
			GENEGURU	-19.13%	6.08%	-7.098%	-5.532%
			BIOSCIENTISTSA	-20.00%	5.21%	1.327%	2.893%
			KMASTRA	-20.01%	5.21%	-0.705%	0.861%
			JACK HARTMANN	-23.97%	1.25%	1.642%	3.208%
			BULBAMAN	-24.19%	1.02%	1.822%	3.388%
			A.J. MULLEN	-25.32%	-0.10%	-1.980%	-0.414%
Average and Median Portfolio Performance
	Avg Recent	Avg YTD	Median Recent		Median YTD
	-$1,507	-33.34%	ETHAN H	-$1,543	MOPGCW	-36.10%
	-2.40%	-33.34%	ETHAN H	-2.182%	MOPGCW	-36.10%

To: technetium who wrote (174)	9/5/2022 6:05:15 PM
From: technetium	Respond to of 267

GNCA still trades? As a bankrupt, delisted zombie stock that fired most of their staff, aside from those needed to keep the lights on, you’d think they’d give up the ghost at some point. No offense intended to anyone who worked there or invested in it. Per Yahoo, their headquarters are located at: 100 Acorn Park Drive 5th Floor Cambridge, MA 02140 Cambridge is a hot bed of biotech, but many companies have their own buildings, rather than a fifth floor office. In the post-covid work from home culture, that office space is probably worth a lot less than it used to be.